Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
published in: Annals of Oncology
date of publication: 2012-09-11
language: English
main subject: phase III clinical trial, non-small-cell lung carcinoma
Cites articles 15
Date
Title
Article - wd:Q44701539